Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Phenoxybenzamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenoxybenzamine SCHEMBL5722 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL50729 | 0.99 | ALDH1A1 (1.00) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL1133740 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL14894820 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| Phenoxybenzamine SCHEMBL11992656 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL15960915 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL19958436 | 0.85 | ALDH1A1 (0.74) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11077715 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11682499 | 0.84 | TSHR (0.72) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B | |
| SCHEMBL11684275 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRALDH1A1CYP2D6ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 969 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | THE DOSHISHA (JP) | 2020-04-23 | — | — | US | claimed |
| EP-3639855-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | The Doshisha (JP) | 2020-04-22 | — | — | EP | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| US-20180296556-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2018-10-18 | — | — | US | claimed |
| US-20170172971-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-06-22 | — | — | US | claimed |
| CN-106610424-A | Screening method of acetylated heat shock protein 90 inhibitor | 复旦大学 | 2017-05-03 | — | — | CN | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| CN-1260980-A | Oral-applied medicine for curing impotence and preparing process thereof | JIANG YANG (CN) | 2000-07-26 | — | — | CN | claimed |
| US-5807574-A | COMPOSITE WITH POLYETHYLENE WAX | ABBOTT LABORATORIES (US) | 1998-09-15 | — | — | US | claimed |
| EP-0818990-A1 | HOMOGENEOUS MIXTURES OF LOW TEMPERATURE-MELTING DRUGS AND ADDITIVES FOR CONTROLLED RELEASE | Abbott Laboratories (US) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031197-A1 | HOMOGENEOUS MIXTURES OF LOW TEMPERATURE-MELTING DRUGS AND ADDITIVES FOR CONTROLLED RELEASE | ABBOTT LABORATORIES (US) | 1996-10-10 | — | — | WO | claimed |
| US-5399581-A | Method and compositions for treatment of sexual impotence | LARAGH JOHN H (US) | 1995-03-21 | — | — | US | claimed |
| US-5261876-A | Enhanced peritoneal membrane plasmapheresis | MONCRIEF-POPOVICH RESEARCH INSTITUTE, INC. (US) | 1993-11-16 | — | — | US | claimed |
| WO-1992011851-A1 | METHOD AND COMPOSITIONS FOR TREATMENT OF SEXUAL IMPOTENCE | LARAGH JOHN H (US) | 1992-07-23 | — | — | WO | claimed |
| US-4832684-A | PROTEIN REMOVAL; INFUSION OF VASODILATOR THEN DRAINAGE | POPOVICH ROBERT P (US) | 1989-05-23 | — | — | US | claimed |
| US-4673385-A | INFUSION OF SOLUTION CONTAINING VASODILATOR THEN DRAINAGE FOR TREATMENT OF PLASMA PROTEIN DISEASES | POPOVICH ROBERT P | 1987-06-16 | — | — | US | claimed |
| US-4022893-A | Treatment for hypertension | MOYER JOHN H | 1977-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | ADRA2B 2044/4885ADRA2C 1373/4885ADRA1A 1240/4885 |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | TGFB1, CASP3, TGFB2 | ADRA2B 3971/4885ADRA2C 4411/4885ADRA1A 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.